Investor Relations

TFF Pharmaceuticals, Inc. is an early-stage biopharmaceutical company focused on the development and commercialization of new inhalation products for the treatment of chronic respiratory diseases and lung conditions.

In early testing the Thin Film Freezing (TFF) proprietary platform significantly improved the solubility of drugs that have poor water solubility.

Mar 10, 2021: TFF Pharmaceuticals Fourth Quarter and Full-Year 2020 Financial and Business Results Conference


TFF Pharmaceuticals Corporate Overview – March 2020


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

March 4, 2021
Phase 1 clinical study report for Voriconazole Inhalation Powder indicated no treatment emergent adverse events at peak plasma levels for   Invasive Pulmonary Aspergillosis Phase 1 Single Ascending Dose study of Tacrolimus Inhalation Powder met and exceeded therapeutic drug levels with a single
February 19, 2021
Company’s Thin Film Freezing maintained efficacy for two different biodefense countermeasures against Alphaviruses and Filoviruses AUSTIN, Texas --(BUSINESS WIRE)--Feb. 19, 2021-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and